| Patient Safety |
1 |
1 |
| Food and Drug Administration (FDA) |
0 |
0.95 |
| Hormonal Therapy |
0 |
0.95 |
| Breast Cancer |
0 |
0.29 |
| Dysfunctional Uterine Bleeding |
0 |
0.27 |
| Menopause |
0 |
0.6 |
| Hysterectomy |
0 |
0.25 |
| Reproductive Endocrinology |
0 |
0.22 |
| Adverse Effects |
0 |
0.5 |
| Breast |
0 |
0.19 |
| Hospital |
0 |
0.19 |
| Testosterone |
0 |
0.19 |
| Uterus |
0 |
0.19 |
| Revenue and Practice Management |
0 |
0.17 |
| Endocrinology |
0 |
0.16 |
| Estrogen |
0 |
0.16 |
| Infertility |
0 |
0.16 |
| Biologic Therapy |
0 |
0.4 |
| Cancer |
0 |
0.13 |
| Texas |
0 |
0.13 |
| Endometrial Cancer |
0 |
0.12 |
| Skin and Soft Tissue Infection |
0 |
0.11 |
| Acne |
0 |
0.4 |
| Anxiety Disorder |
0 |
0.3 |
| Weight Management |
0 |
0.3 |
| Anxiety |
0 |
0.4 |
| California |
0 |
0.06 |
| Hair |
0 |
0.06 |
| Hemorrhage |
0 |
0.06 |
| Mood Swings |
0 |
0.06 |
| Pennsylvania |
0 |
0.06 |
| Weight Gain |
0 |
0.06 |
| Peanut Allergy |
0 |
0.05 |
| Addiction |
0 |
0.03 |
| Allergy |
0 |
0.03 |
| Antioxidant |
0 |
0.03 |
| Cardiovascular disease |
0 |
0.03 |
| Cardiovascular Risk Management |
0 |
0.03 |
| Drug and Treatment Safety |
0 |
0.03 |
| Endometriosis |
0 |
0.03 |
| Gluteal Region |
0 |
0.03 |
| Health Care Reform |
0 |
0.03 |
| Hormone Replacement Therapy |
0 |
0.03 |
| Hypogonadism |
0 |
0.03 |
| Mammogram |
0 |
0.03 |
| Meningitis |
0 |
0.03 |
| Meningococcal Disease |
0 |
0.03 |
| Outbreak |
0 |
0.03 |
| Outpatient Clinic |
0 |
0.03 |
| Overdose |
0 |
0.03 |
| Peer Review |
0 |
0.03 |
| Postmenopausal Bleeding |
0 |
0.03 |
| Primary Care |
0 |
0.03 |
| Private Practice |
0 |
0.03 |
| Tennessee |
0 |
0.03 |
| Vagina |
0 |
0.03 |
| Vitamin |
0 |
0.03 |